[Levamisole and splenin in combined therapy of patients with bronchiectasis].
Follow-up of 114 patients with bronchiectasis has demonstrated that immunomodulation agents levamisole and splenin included in combined treatment augment their therapeutic effect and normalize the immune status of patients. This is manifested by normalization of the amount and functional activity to T-lymphocytes, the content of IgG, IgM and IgA and the autoimmune shifts. A favourable effect was encountered significantly more often than that in patient who were treated by the traditional methods without the use of the immunomodulation agents and in those who were given only levamisole and splenin together with anti-bacterial and hygienic therapy.
Sokhin
A A
AA
Monogarova
N E
NE
Zeligman
V S
VS
Chernykh
S N
SN
Radugina
G S
GS
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001987:Bronchiectasis / Q000188:drug therapy* / Q000276:immunology; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage*; D008875:Middle Aged; D013154:Spleen; D013424:Sulfanilamides / Q000008:administration & dosage; D013946:Thymopoietins / Q000008:administration & dosage*; D013951:Thymus Hormones / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D013424:Sulfanilamides; D013946:Thymopoietins; D013951:Thymus Hormones; D007978:Levamisole; C032841:thymopoietin III
Levamizol i splenin v kompleksnoĭ terapii bol'nykh bronkhoéktaticheskoĭ bolezn'iu.